Cellerant Therapeutics is a privately-held, clinical-stage biotechnology company with a portfolio of novel innate and adaptive immunotherapies for oncology and blood-related disorders, including cell-based and antibody therapeutics. Cellerant's lead product, CLT-008, is a myeloid progenitor cell therapy currently in Phase 2 clinical development in patients with acute myeloid leukemia (AML). The Company also has a Cancer Stem Cell (CSC) antibody discovery program focused on therapies for AML, multiple myeloma and myelodysplastic syndrome.
Cellerant's Press Releases
March 17, 2015
Cellerant Announces Dosing of First Patient in Randomized Phase 2 Clinical Trial of CLT-008 in Acute Myeloid Leukemia Patients
December 5, 2014
Cellerant to Present Phase 1 Clinical Data on Evaluation of CLT-008 in Patients with Acute Myeloid Leukemia at the 2014 American Society of Hematology Annual Meeting
September 11, 2014
Cellerant Therapeutics awarded $47.5 million under existing U.S. Government contract to support development of CLT-008.